Dr. Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award
Pharmacoepidemiologist at Sanofi | France
Dr. Sandrine Colas is a Senior Pharmacoepidemiologist with over a decade of expertise in pharmacoepidemiology, biostatistics, and real-world data research. She has led global pharmacovigilance initiatives, innovative AI-driven projects, and regulatory strategies at renowned institutions like Sanofi, IQVIA, and EPIPHARE-ANSM. With extensive experience in risk-benefit assessment, AI and NLP applications in healthcare, and cross-functional collaboration, she has significantly impacted regulatory decision-making and scientific dissemination. Dr. Colas is widely recognized for her operational excellence, leadership, and contributions to real-world evidence studies, presenting at major scientific forums and mentoring future experts in pharmacoepidemiology and public health research.
Publication Profile
Orcid
Education
Dr. Sandrine Colas holds a Ph.D. in Public Health, Epidemiology from Université Paris-Saclay, where she specialized in pharmacoepidemiology and advanced biostatistics. She also earned an MSc in Public Health, Epidemiology from Université Paris-Sud and another MSc in Food Industries Technologies from ENSAIA, strengthening her interdisciplinary foundation. Additionally, she completed a degree in Biomedical Engineering at UTC/ENSP, gaining technical and analytical expertise essential for healthcare data analysis and medical research. This diverse educational background has enabled her to integrate statistical modeling, real-world data analytics, and public health perspectives to address complex issues in drug safety and healthcare innovation.
Experience
Dr. Sandrine Colas currently serves as Senior Pharmacoepidemiologist at Sanofi R&D, leading the Valproate PASS Program, TANGO study, and AI-based healthcare innovations while collaborating with PRAC/EMA regulatory bodies. She previously directed epidemiological research at IQVIA, managing real-world evidence studies and regulatory responses. At EPIPHARE-ANSM, she contributed to post-authorization safety studies (PASS), risk management plans (RMPs), and mentored postgraduate students. Across roles, she has excelled in cross-functional collaboration, strategic leadership, scientific presentations, and regulatory submissions. Her work integrates real-world evidence, AI analytics, and clinical data insights, shaping global pharmacovigilance practices and improving drug safety monitoring in real-world healthcare settings.
Awards and Honors
Dr. Sandrine Colas has received multiple recognitions for her leadership and scientific contributions. At Sanofi, she earned the 2022 Development Award for Operational Excellence and Outstanding Impact Awards in 2022 and 2024 for her role in AI-driven pharmacovigilance innovations. Her pioneering work on AI-NLP-LLM applications in healthcare research was ranked among the Top 5% Abstracts at ISPOR 2024, where she also won the Best Podium Award. She has presented widely at international conferences including ISPE, EBMT, and ISPOR, reflecting her commitment to advancing pharmacoepidemiology, regulatory science, and real-world data analytics through high-impact publications and innovative research methodologies.
Research Focus
Dr. Sandrine Colas specializes in pharmacoepidemiology, regulatory science, and real-world data analytics. Her research focuses on drug safety, post-authorization studies, and risk-benefit assessments using large healthcare datasets like SNDS. She has integrated AI, natural language processing (NLP), and advanced analytics to enhance drug surveillance, predict adverse outcomes, and support regulatory decision-making. Her interests also include AI-driven pharmacovigilance innovations, real-world evidence generation, and methodological advancements in epidemiological research. Through cross-disciplinary collaboration, she aims to strengthen evidence-based regulatory policies, optimize patient safety strategies, and bridge the gap between clinical research, real-world practice, and global health policy in pharmaceutical development.
Publication Top Notes
Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine
Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases
Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases
Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France
Exchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients
Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients
Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship
Inondation des capteurs de pression sanguine des générateurs–moniteurs d’hémodialyse
Conclusion
Given her leadership in pharmacovigilance research, AI-based healthcare innovations, and extensive real-world data studies, Dr. Sandrine Colas is a strong candidate for the Pharmaceutical Research Impact Award. Her impactful publications, regulatory contributions, and commitment to improving drug safety and healthcare decision-making reflect the award’s core values. With minor expansions into emerging interdisciplinary fields, she could further solidify her status as a global leader in pharmaceutical research innovation and evidence-based healthcare advancements.